Melanoma News and Research

Latest Melanoma News and Research

Patients with Inflammatory Bowel Disease may be at risk for developing non-melanoma skin cancer

Findings from a new retrospective cohort study presented at the American College of Gastroenterology's 74th Annual Scientific meeting in San Diego indicate that patients with Inflammatory Bowel Disease (IBD), especially those receiving the thiopurine class of medications to treat IBD, may be at risk for developing non-melanoma skin cancer (NMSC).

27 Oct 2009

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA.

26 Oct 2009

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Based on an extensive review of the highest quality scientific literature on psoriasis and the opinion of recognized psoriasis experts, the American Academy of Dermatology (Academy) has released new guidelines of care for the management and treatment of psoriasis with ultraviolet (UV) light therapy, also known as phototherapy. Recommendations for the use of the most common forms of UV light therapy, as stand-alone treatments or in conjunction with other therapies, were outlined, including patient considerations.

23 Oct 2009

Schering-Plough announces 2009 third quarter financial results

Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2009 third quarter.

22 Oct 2009

EMEA informs Antigenics on a negative opinion for Oncophage MAA

Antigenics Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMEA), has verbally informed the Company at an oral meeting to anticipate a negative opinion on the marketing authorization application (MAA) for Oncophage (vitespen) in early-stage, localized renal cell carcinoma (kidney cancer).

21 Oct 2009

DUSA Pharmaceuticals finds place in Deloitte's Technology Fast 500 list for second consecutive year

DUSA Pharmaceuticals, Inc.(R)( )(Nasdaq: DUSA), a specialty pharmaceutical company focused on dermatology, announced today that it has been named to Deloitte's Technology Fast 500 list. For the second consecutive year, Deloitte recognized DUSA as one of the Top 500 fastest growing technology, media, telecommunications and life sciences companies in North America in terms of percentage revenue growth over a five year period.

21 Oct 2009

Delcath Systems completes its pivotal Phase III Metastatic Melanoma Trial enrollment

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that its pivotal Phase III Metastatic Melanoma Trial has met its goal of 92 patients and is fully enrolled.

21 Oct 2009

Contribution of glycosaminoglycans to skeletal abnormalities in patients with lysosomal storage diseases demonstrated

A group led by Dr. Dieter Br-mme at the University of British Columbia has demonstrated that glycosaminoglycans (GAGs) contribute to skeletal abnormalities in patients with lysosomal storage diseases. Their report can be found in the November 2009 issue of The American Journal of Pathology.

21 Oct 2009

Palmerolide A: Real hope for cancer treatment

A targeted chemotherapy for the treatment of skin cancer is one step closer, after a team of University of Alberta researchers successfully synthesized a natural substance that shows exceptional potential to specifically treat this often fatal disease.

21 Oct 2009

Manhattan Scientifics enters into a non-binding LOI with Edward R. Flynn

Manhattan Scientifics announced today that it has entered into a non-binding letter of intent (LOI) with Edward R. Flynn, Ph.D. and his company, Senior Scientific, LLC, to acquire all the manufacturing and marketing rights, together with all commercial rights associated with Dr. Flynn’s patents and IP in the emerging field of nanomedicine.

21 Oct 2009

Health care providers should assist patients in breaking the smoking habit

More than a quarter of cancer survivors who still smoke have not been advised to quit smoking by their health care providers in the last year, according to a study published by researchers at Fox Chase Cancer Center in the current issue of the Journal of General Internal Medicine.

21 Oct 2009

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks.

19 Oct 2009

Antisense Pharma's SAPPHIRE Phase III trial evaluating trabedersen approved by Health Canada

The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received the approval by Health Canada for its pivotal Phase III clinical trial SAPPHIRE in patients with recurrent or refractory anaplastic astrocytoma.

19 Oct 2009

Findings provide new insight on skin pigmentation

The skin's pigment cells can be formed from completely different cells than has hitherto been thought, a new study from the Swedish medical university Karolinska Institutet shows. The results, which are published in the journal Cell, also mean the discovery of a new kind of stem cell.

19 Oct 2009

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa dose escalation study of patients suffering from idiopathic CD4 lymphocytopenia (ICL).

15 Oct 2009

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States. The program is already in progress in Australia, where it was initiated in June 2009.

14 Oct 2009

NY Senators co-sponsors bill to establish comprehensive program for lung cancer

Today, Lung Cancer Alliance (LCA) hailed the support of Senators Chuck Schumer (D-NY) and Kirsten Gillibrand (D-NY) who have signed on as co-sponsors of a bill to establish the first ever multi-agency, comprehensive program targeted at lung cancer.

14 Oct 2009

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Provectus Pharmaceuticals, Inc., a development stage oncology and dermatology biopharmaceutical company, has completed patient accrual and initial treatment in its Phase 2 trial of PH-10 for the treatment of plaque psoriasis. This milestone marks the third Phase 2 clinical trial for which Provectus has completed patient accrual since May 2009.

13 Oct 2009

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRYSM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O’Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California.

12 Oct 2009

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Plexxikon Inc. today announced that dosing of cancer patients with PLX3397 has started in a Phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating multiple diseases, including metastatic cancer and rheumatoid arthritis.

9 Oct 2009

Melanoma News and Research

Latest Melanoma News and Research

Patients with Inflammatory Bowel Disease may be at risk for developing non-melanoma skin cancer

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Schering-Plough announces 2009 third quarter financial results

EMEA informs Antigenics on a negative opinion for Oncophage MAA

DUSA Pharmaceuticals finds place in Deloitte's Technology Fast 500 list for second consecutive year

Delcath Systems completes its pivotal Phase III Metastatic Melanoma Trial enrollment

Contribution of glycosaminoglycans to skeletal abnormalities in patients with lysosomal storage diseases demonstrated

Palmerolide A: Real hope for cancer treatment

Manhattan Scientifics enters into a non-binding LOI with Edward R. Flynn

Health care providers should assist patients in breaking the smoking habit

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

Antisense Pharma's SAPPHIRE Phase III trial evaluating trabedersen approved by Health Canada

Findings provide new insight on skin pigmentation

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

NY Senators co-sponsors bill to establish comprehensive program for lung cancer

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Innovation in neuroscience drug discovery - eBook eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Melanoma News and Research

Latest Melanoma News and Research

Innovation in neuroscience drug discovery - eBook eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in